MV
Michel Vounatsos at Biogen (NAS: BIIB)
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan
ContactFirm
Biogen (NAS: BIIB)
Location
Japan
Investment Stage
Growth
Geographic Focus
JapanAsia
About Michel Vounatsos
Enriching content...
Similar Investors in Asia
Contact Biogen (NAS: BIIB)
Get in touch for investment criteria and partnership opportunities.
Contact